Glaxo Wellcome's Second Act
The company faces a series of challenges that attack head-on one of the most successful franchises in drug industry history. New approaches to treating ulcers, combination therapies that eradicate the bacteria that causes the disease rather than simply treat its symptoms, will likely lead to an overall decrease in the use of H2 antagonists. Even more threatening for Glaxo Wellcome is the pending genericization of Zantac (ranitidine). The question the company faces: will the same strategies that helpe
You may also be interested in...
Emer Cooke seems set to take over as head of the European Medicines Agency – one of the world's most powerful regulatory bodies – before the end of the year. We report on the reaction of a range of pharmaceutical sector stakeholders to her nomination.
Clif Bar didn’t convince National Advertising Division a challenge by Kind is too “complex” for the SWIFT forum. NAD attorneys determined Clif didn’t support its claims of sustained energy and “better” performing ability.
Beauty Market News: China Cosmetics Regulations Modernized, Florida Stops Local Oxybenzone Bans, More
L’Oreal acquires Thayers Natural Remedies; Unilever, L’Oreal remove ‘whitening,’ ‘fair’ from labels; China finalizes modernization of cosmetics regulations; and Florida governor signs law preventing local bans on oxybenzone.